| The Codexis Story: A Tangled Partnership Web Greentech Media submits: by Chet GeschickterCodexis (CDXS) is hoping that its IPO will break the biofuel industry's losing streak and signal its ascendancy as a shining star in the space. Management claims it has a four-pronged business model with significant upside and limited risk. And the CEO has a British accent! Management is quick to point out that it's a biotech company participating in the biofuel market. Not a biofuel company messing around with biotechnology and falling into the "valley of death" trap. Codexis argues that a partnership with Shell (RDS.A), a big patent portfolio and savvy genetic engineering are the underpinnings of its super business model. But for now, it's a story, not a proven model. And the story is an optimistic version of how a tangled partnership web will play out.Complete Story » seekingalpha.com |
Enzo Biochem Reports Third Quarter Operating Results (Business Wire) NEW YORK----Enzo Biochem, Inc. , a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, today reported financial results for the three and nine months ended April 30, 2010. us.rd.yahoo.com |
The Story of Faridah - Video Global Health Leader, PSI, Launches Impact Magazine feedproxy.google.com |
Interview: Cleveland BioLabs CEO Discusses Recent Developments, Milestones Ahead M.E. Garza submits: We are hearing some very loud and credible chatter that long-awaited good news may be coming for Cleveland BioLabs (CBLI), the company that engages in the discovery, development, and commercialization of products for human protection from radiation.In the first quarter of this year, the company submitted additional paperwork about Protectan CBLB502 (a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy) to a potential customer - the U.S. Government's Department of Defense. Many on Wall Street believe that the company has the best chance of not only getting significant funding from the DoD, but also a potentially bigger order from the Biomedical Advanced Research and Development Authority (BARDA) who would acquire doses of the drug for the Strategic National Stockpile.Complete Story » seekingalpha.com |
Lawmakers to Question Egg-Farm Executives Lawmakers on Wednesday will question executives from the companies involved in the summer egg recall, while consumer advocates lobby for tougher food-safety regulations. online.wsj.com |